 Patients receive depsipeptide romidepsin intravenously IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response CR receive 6 additional courses beyond documentation of CR. 